Sarepta Buoyed As Rival Craters On Muscular Dystrophy Drug Ruling – Investor’s Business Daily
Investor’s Business Daily |
Sarepta Buoyed As Rival Craters On Muscular Dystrophy Drug Ruling
Investor’s Business Daily Schwartz noted the stock reaction is likely exacerbated by the resignation of an advisor worried about the therapy. Dr. James Wilson expressed worries over the treatment in January when he resigned from Solid Bio’s scientific advisory board. “Solid is … |
Los Angeles Times |
Erectile dysfunction becomes the new frontier for stem–cell clinics hawking unproven ‘treatments’
Los Angeles Times That’s because the marketing of “stem–cell” treatments for a panoply of medical ailments already has become infected with “unscrupulous hype,” in the words of Scott Gottlieb, commissioner of the Food and Drug Administration. Gottlieb made the remark … |
Endpoints News |
CRISPR pioneer Feng Zhang launches a ‘limitless’ biotech upstart with big plans for speeding new drug development
Endpoints News The biotech came out of stealth mode today with a $15.6 million round, which we’ve been tracking, and a plan to employ the CRISPR system with a platform tech built around artificial intelligence, genome sequencing, gene synthesis and screening efforts … Stealth biotech Arbor steps out of the shadows, announcing it’s found a new CRISPR enzymeSTAT Arbor Biotechnologies Discovers New CRISPR System Utilizing its Discovery PlatformForexTV.com |